Danaher Corporation (DHR)vsFulgent Genetics Inc (FLGT)
DHR
Danaher Corporation
$184.30
-0.38%
HEALTHCARE · Cap: $117.48B
FLGT
Fulgent Genetics Inc
$18.14
-2.99%
HEALTHCARE · Cap: $543.87M
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 7635% more annual revenue ($24.78B vs $320.35M). DHR leads profitability with a 14.9% profit margin vs -23.0%. DHR appears more attractively valued with a PEG of 1.09. DHR earns a higher WallStSmart Score of 58/100 (C).
DHR
Buy58
out of 100
Grade: C
FLGT
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-60.8%
Fair Value
$114.63
Current Price
$184.30
$69.67 premium
Margin of Safety
+54.8%
Fair Value
$50.88
Current Price
$18.14
$32.74 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.1B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
3.7% revenue growth
ROE of 7.0% — below average capital efficiency
Smaller company, higher risk/reward
ROE of -7.0% — below average capital efficiency
Revenue declined 3.2%
Earnings declined 98.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : FLGT
The strongest argument for FLGT centers on Price/Book, Debt/Equity, Altman Z-Score. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : FLGT
The primary concerns for FLGT are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
DHR profiles as a value stock while FLGT is a turnaround play — different risk/reward profiles.
FLGT carries more volatility with a beta of 0.92 — expect wider price swings.
DHR is growing revenue faster at 3.7% — sustainability is the question.
DHR generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (58/100 vs 40/100). FLGT offers better value entry with a 54.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Fulgent Genetics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?